Total Autologous Angiogenic Therapy with Cultured Bone Marrow Derived Mesenchymal Stromal Cells Grown in Platelet-Rich Plasma Against Peripheral Arterial Disease. - Advanced Medical Care -

Total Autologous Angiogenic Therapy with Cultured Bone Marrow Derived Mesenchymal Stromal Cells Grown in Platelet-Rich Plasma Against Peripheral Arterial Disease. - Advanced Medical Care - - TAAT Advance

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTb030210146

Enrollment

Registered

2021-06-11

Start date

2022-10-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral arterial disease

Interventions

Under venous anesthesia, bone marrow was aspirated from iliac bone. Mesenchymal stromal cells derived from bone marrow was cultured with autologous platelet-rich plasma for 1 to 2 weeks. Concentrated

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: # Patients with Severe PAD (Peripheral Arterial Disease) # 20<= Age <=80 # informed consent

Exclusion criteria

Exclusion criteria: # A past 3 months or current history of alcoholism or drug dependence # A past 5 years or current history of malignant disease # Untreated diabetic retinopathy # No informed consent # Others

Design outcomes

Primary

Measure	Time frame
# Limb salvage ratio	—

Secondary

Measure	Time frame
# size of skin ulcer # 6-minute walking test # visual analog scale (VAS) # TcPO2 (Transcutaneous partial pressure of oxygen) # SPP (Skin perfusion pressure) # ABPI (Ankle brachial pressure index) # SF-12 (Physical and mental health scores) # Fontaine classification # Rutherford classification # Safety assessment	—

Countries

Japan

Contacts

Public ContactKunihiko Matsubara

Tokyo Medical University Hospital

k-matu74@tokyo-med.ac.jp+81-3-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026